AR085266A1 - Uso de nifuratel para tratar infecciones causadas por especies de clostridium - Google Patents

Uso de nifuratel para tratar infecciones causadas por especies de clostridium

Info

Publication number
AR085266A1
AR085266A1 ARP120100532A ARP120100532A AR085266A1 AR 085266 A1 AR085266 A1 AR 085266A1 AR P120100532 A ARP120100532 A AR P120100532A AR P120100532 A ARP120100532 A AR P120100532A AR 085266 A1 AR085266 A1 AR 085266A1
Authority
AR
Argentina
Prior art keywords
nifuratel
infections caused
species
treat infections
treat
Prior art date
Application number
ARP120100532A
Other languages
English (en)
Inventor
Federico Mailland
Giuliana Iob
Anna Bulgheroni
Original Assignee
Polichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polichem Sa filed Critical Polichem Sa
Publication of AR085266A1 publication Critical patent/AR085266A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de nifuratel, o una sal fisiológicamente aceptable del mismo, para tratar infecciones causadas por especies de bacterias del género Clostridium. Uso de nifuratel para tratar la infección de Clostridium difficile (CDI) y en particular Clostridium difficile asociada con diarrea (CDAD).Reivindicación 12: Nifuratel de acuerdo con la reivindicación 11, caracterizado en que dicho al menos un antibiótico es seleccionado de: metronidazol, vancomicina, bacitracina, rifaximina, aminoglucósidos tal como neomicina, gentamicina, amikacina, kanamicina y sales de los mismos. Reivindicación 13: Nifuratel de acuerdo con la reivindicación 11, caracterizado en que dicho al menos un agente antidiarreico es seleccionado de: subsalicilato de bismuto, sílice de aluminio, caolín, carbón activado, loperamida, atapulgita y cinc. Reivindicación 14: Nifuratel de acuerdo con la reivindicación 11, caracterizado porque dicho al menos un probiótico es seleccionado de la especie del género Lactobacillus, Bacillus clausii y Saccharomyces bouillardii.
ARP120100532A 2011-02-22 2012-02-16 Uso de nifuratel para tratar infecciones causadas por especies de clostridium AR085266A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11155283A EP2491929A1 (en) 2011-02-22 2011-02-22 Use of Nifuratel to treat infections caused by Clostridium species

Publications (1)

Publication Number Publication Date
AR085266A1 true AR085266A1 (es) 2013-09-18

Family

ID=44059064

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120100532A AR085266A1 (es) 2011-02-22 2012-02-16 Uso de nifuratel para tratar infecciones causadas por especies de clostridium

Country Status (24)

Country Link
EP (2) EP2491929A1 (es)
KR (1) KR20140021525A (es)
CN (1) CN103384523B (es)
AR (1) AR085266A1 (es)
BR (1) BR112013015974A2 (es)
CL (1) CL2013002098A1 (es)
CY (1) CY1116210T1 (es)
DK (1) DK2678015T3 (es)
EA (1) EA025645B1 (es)
ES (1) ES2529210T3 (es)
GE (1) GEP20156264B (es)
HK (1) HK1187553A1 (es)
HR (1) HRP20150141T1 (es)
ME (1) ME02056B (es)
MX (1) MX341213B (es)
PL (1) PL2678015T3 (es)
PT (1) PT2678015E (es)
RS (1) RS53739B1 (es)
SI (1) SI2678015T1 (es)
SM (1) SMT201500039B (es)
TW (1) TWI536989B (es)
UA (1) UA113159C2 (es)
UY (1) UY33915A (es)
WO (1) WO2012113594A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102885793B (zh) * 2012-10-15 2014-08-20 山东罗欣药业股份有限公司 一种硝呋太尔组合物片剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000255A1 (en) * 2001-06-25 2003-01-03 Essential Therapeutics, Inc. Novel nitrofuran-containing heterocyclic compounds and uses thereof
EP2243482A1 (en) 2009-04-20 2010-10-27 Polichem SA Use of nifuratel to treat infections caused by atopobium species

Also Published As

Publication number Publication date
BR112013015974A2 (pt) 2018-06-05
EP2678015B1 (en) 2014-11-26
UY33915A (es) 2012-04-30
MX341213B (es) 2016-08-11
DK2678015T3 (en) 2015-01-26
MX2013009686A (es) 2013-12-06
SI2678015T1 (sl) 2015-03-31
ES2529210T3 (es) 2015-02-18
CL2013002098A1 (es) 2014-06-06
CN103384523A (zh) 2013-11-06
CY1116210T1 (el) 2017-02-08
TWI536989B (zh) 2016-06-11
EA201370179A1 (ru) 2014-03-31
GEP20156264B (en) 2015-03-25
WO2012113594A1 (en) 2012-08-30
EP2678015A1 (en) 2014-01-01
UA113159C2 (xx) 2016-12-26
TW201309292A (zh) 2013-03-01
RS53739B1 (en) 2015-06-30
PT2678015E (pt) 2015-02-10
HRP20150141T1 (en) 2015-03-13
SMT201500039B (it) 2015-03-05
PL2678015T3 (pl) 2015-04-30
EA025645B1 (ru) 2017-01-30
EP2491929A1 (en) 2012-08-29
HK1187553A1 (en) 2014-04-11
ME02056B (me) 2015-05-20
KR20140021525A (ko) 2014-02-20
CN103384523B (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
ES2561253T3 (es) Bacterias probióticas que tienen actividad antioxidante y uso de las mismas
MX2022006525A (es) Activo de polipeptidos de lisina contra bacterias gram-negativas.
CL2015003120A1 (es) Cepas bacterianas que poseen actividad antimicrobiana y composiciones de control biológico que las contienen
CO7270459A2 (es) Composiciones que comprenden un agente de control biológico y fungicida
WO2017017631A3 (en) Antibacterial therapeutics and prophylactics
CO7270456A2 (es) Composición que comprende un agente de control biológico y un fungicida
AU2012302022A8 (en) Antibacterial compounds and methods for use
MX2016009898A (es) Tratamientos para acne resistente.
CL2015000986A1 (es) Composiciones útiles en el tratamiento y control de enfermedades en plantas y métodos asociados.
AR091196A1 (es) Composicion que comprende un agente de control biologico y un fungicida
CO2020016675A2 (es) Tiofenocarboxamidas sustituidas y análogos como agentes antibacterianos
AR091197A1 (es) Composicion que comprende un agente de control biologico y un fungicida
BR112014027842A2 (pt) bacteriófago lisina e combinações de antibióticos contra bactérias gram-positivas
CO2019011264A2 (es) Nanosistemas que comprenden plata y antibióticos y su uso para el tratamiento de infecciones bacterianas
WO2017218922A3 (en) Compositions and methods for the treatment of bacterial infections
BR112015026193B8 (pt) Composição farmacêutica, método para formular uma composição farmacêutica, uso da composição farmacêutica, método para inibir a formação de biofilme em uma superfície, e, artigo fabricado para curativo
PH12016501532A1 (en) Antibacterial combinations comprising polymyxin
WO2013041663A3 (de) Modifizierte apidaecinderivate als antibiotische peptide
MX2018007158A (es) Uso de compuestos fenolicos derivados de arandano como agente sinergizante antibiotico contra bacterias patogenicas.
WO2020014501A8 (en) Compositions and methods for the treatment of bacterial infections
AR085266A1 (es) Uso de nifuratel para tratar infecciones causadas por especies de clostridium
BR112017019534A2 (pt) substrato fibroso para captura de bacterias gram-negativas
WO2016191695A3 (en) Treatments for obligately intracellular infections
WO2018140707A8 (en) Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces
Venkat Ramanan et al. Changing profile of pediatric community-acquired UTI in a hospital in South India

Legal Events

Date Code Title Description
FB Suspension of granting procedure